Physician profile
Kenneth E Roberts
NPI 1598732521
$3,466.09
in general payments reported to CMS, 2019-2025
17 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $434 · 2021: $420 · 2022: $725 · 2023: $619 · 2024: $682 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,537 · Education: $40.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.83 |
| Education | $40.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $866.96 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $842.24 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $581.71 | 2021-2025 | Verquvo, Steglatro |
| Supernus Pharmaceuticals, INC. | $320.98 | 2019-2022 | |
| Abbvie INC. | $162.48 | 2021-2024 | Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $150.25 | 2019-2024 | |
| Lilly USA, LLC | $149.12 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $87.07 | 2022 | |
| Xeris Pharmaceuticals, INC. | $64.02 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $57.14 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.30 | 2023 | |
| Novo Nordisk INC | $41.91 | 2020-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $25.66 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $21.05 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $18.65 | 2025 | Aristada, Lybalvi |
| Amgen INC. | $14.70 | 2024 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.